Erasca

Erasca, Inc. has priced an upsized public offering of common stock, securing $225 million in gross proceeds. This capital infusion, at $10.00 per share, will advance the company’s pipeline of therapies for RAS/MAPK pathway-driven cancers. The funds are earmarked for research and development, supporting product candidates, and general corporate purposes, reflecting strong investor confidence.